In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Peifei LiuCenter for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.ORCID 0009-0000-9707-7810 Yizhen PangCenter for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.ORCID 0000-0001-7710-5925 Cuicui LiCenter for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.ORCID 0000-0002-0077-727X Yuqi HuaDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.ORCID 0009-0001-8279-6051 Wenyao ZhenDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.ORCID 0000-0002-7619-0109 Tianzhi ZhaoDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.ORCID 0009-0001-3250-8445 Xiaobin ZhaoDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.ORCID 0000-0003-2390-1912 Jie LiuCenter for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.ORCID 0000-0003-2931-2756 Bingyu LiCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.ORCID 0009-0003-7096-9511 Jinming YuCenter for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.ORCID 0000-0002-3824-2713 Xiaoyuan ChenCenter for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.ORCID 0000-0002-9622-0870 Jingjing ZhangDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.ORCID 0000-0002-6948-1813 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Therapeutic antibodies and antibody-drug conjugates are limited by large molecular size, poor tumor penetration, and signaling-adaptive resistance. We introduce an engineering strategy for radiotherapeutic antibody fragments in which an albumin-binding domain (ABD) rebalances molecular size and pharmacokinetics. Using human epidermal growth factor receptor 2 (HER2) as a proof of concept, we developed
Indexed as
AlbuminsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesImmunoglobulin Fab FragmentsLutetiumRadioisotopesRadiopharmaceuticalsAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorFemaleHumansMiceProtein BindingTrastuzumabXenograft Model Antitumor AssaysAlbuminsAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesImmunoglobulin Fab FragmentsLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsTrastuzumab
Identifiers
PMID42467791
PMCPMC13378577
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390